StockNews.AI
NEPH
StockNews.AI
4 hrs

Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water

1. Nephros launches a new filter to reduce Total PFAS in water. 2. The filter targets a growing concern over health threats from PFAS contaminants. 3. Independently tested, it also reduces lead, asbestos, chlorine, and taste. 4. The product is ideal for critical water safety industries like healthcare. 5. Increasing regulatory focus on water safety may drive demand for the filter.

5m saved
Insight
Article

FAQ

Why Bullish?

The launch addresses a pressing market need for safe drinking water solutions. Previous innovations in filtration, such as those targeting E. coli, have positively impacted company valuations.

How important is it?

The regulatory environment is shifting towards stricter water safety, amplifying the relevance of Nephros' products. This heightened attention directly ties to potential revenue growth, making it an important development for NEPH.

Why Long Term?

The increasing regulatory scrutiny on PFAS supports long-term demand for Nephros products. Similar trends in other environmental health sectors have shown sustained market growth over several years.

Related Companies

AOSXRXGEEWLNT
SOUTH ORANGE, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to medical and commercial markets, today announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros’ portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention. PFAS, sometimes referred to as “forever chemicals,” are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health. “Unlike most filters that only address PFOA and PFOS, the Nephros 19-Series PFAS Filter has been independently tested to reduce Total PFAS, offering protection against a much broader spectrum of contaminants,” said Robert Banks, President & CEO of Nephros. “By combining PFAS reduction with protection against lead, asbestos, and other hazards, we believe the 19-Series PFAS Filter helps set a new benchmark in support of safer, more reliable drinking water.” Key Features of the Nephros 19-Series PFAS Filter Independently tested to NSF Standards 42 and 53Validated reduction of Total PFAS, including PFOA and PFOSEffectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste, and odor3,145-gallon capacity with a 1.63 GPM flow rateProvides long-term protection against persistent, health-threatening waterborne contaminants The Nephros 19-Series PFAS filter is ideal for industries and facilities where water safety is critical, including healthcare, daycares, education, foodservice, and manufacturing. For more information, including performance data, please visit the Nephros 19-Series Filter product page on our website. About NephrosNephros is a leading provider of filtration products to medical and commercial markets, offering a wide range of solutions that deliver superior filtration performance. With advanced hollow-fiber technology and effective commercial filter media, Nephros products help protect against waterborne contaminants, ensuring the highest level of water quality. For more information about Nephros, visit nephros.com Forward-Looking StatementsThis release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected benefits of the 19-Series PFAS Filter and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ dependence on third-party manufacturers, distributors and researchers, changes in business and competitive conditions and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release. Investor Relations Contacts:Kirin Smith, PresidentPCG Advisory, Inc.(646) 823-8656ksmith@pcgadvisory.com Robert Banks, CEONephros, Inc.(201) 343-5202robert.banks@nephros.com Judy Krandel, CFONephros, Inc.(201) 343-5202judy.krandel@nephros.com

Related News